Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital

Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Humacyte in a report on Wednesday.

Humacyte, Inc. (HUMA) Stock Analysis: Exploring A 268% Potential Upside In Biotechnology

Investors with a penchant for biotechnology may find Humacyte, Inc. (NASDAQ: HUMA) an intriguing prospect. The company, headquartered in Durham, North Carolina, is at the forefront of developing off-the-shelf, implantable human tissues, potentially revolutionizing treatments across several therapeutic areas. With a market capitalization of $414.17 million, Humacyte is making waves in the healthcare sector, specifically within the biotechnology i…